Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 1:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 85 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Arrhythmia Prophylaxis Clear all
Completed No phase listed Observational Accepts healthy volunteers

Home Monitoring for Atrial Fibrillation Using a Microlife Blood Pressure Monitor

NCT00861354
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Microlife blood pressure monitor with AF detection (Microlife AFIB MLU3MQ1)
Device
Lead sponsor
Microlife
Industry
Eligibility
21 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Flushing, New York
Source: ClinicalTrials.gov public record
Updated Jan 8, 2010 · Synced Oct 21, 2026, 1:35 AM EDT
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation

NCT00403767
View directory record Official record
Conditions
Atrial Fibrillation, Stroke, Embolism
Interventions
Rivaroxaban, Warfarin, Matching placebo for Rivaroxaban arm (Warfarin placebo), Matching placebo for Warfarin arm (Rivaroxaban placebo)
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years and older
Enrollment
14,269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
295
States / cities
Birmingham, Alabama • Dothan, Alabama • Geneva, Alabama + 292 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2014 · Synced Oct 21, 2026, 1:35 AM EDT
Withdrawn Phase 2 Interventional

Minocycline Plus Amiodarone Versus Amiodarone Alone for the Prevention of Atrial Fibrillation After Cardiac Surgery

NCT01422148
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Amiodarone, Minocycline
Drug
Lead sponsor
Baystate Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Melrose, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 21, 2026, 1:35 AM EDT
Terminated Phase 4 Interventional

Secondary Prevention of Atrial Fibrillation (Impact of Renin-Angiotensin-Aldosterone System Inhibition)

NCT01233635
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
no drug, start cozaar, continue cozaar
Other · Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 23, 2023 · Synced Oct 21, 2026, 1:35 AM EDT
Completed Not applicable Interventional Results available

Evaluation of the CIRCA Monitoring System in Prevention of Esophageal Lesions Following RFCA

NCT02467166
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Circa™ Probe
Device
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jun 2, 2021 · Synced Oct 21, 2026, 1:35 AM EDT
Not yet recruiting Not applicable Interventional

Computerized Decision Support to Prevent Stroke in Atrial Fibrillation

NCT06355986
View directory record Official record
Conditions
Atrial Fibrillation, Stroke
Interventions
Alert-based computerized decision support
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Edgewood, Kentucky • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 21, 2026, 1:35 AM EDT
Completed Phase 4 Interventional Results available

The Use of Dual Chamber ICD With Special Programmed Features to Lower the Risk of Inappropriate Shock

NCT00787800
View directory record Official record
Conditions
Ventricular Tachycardia, Ventricular Fibrillation, Atrial Fibrillation, Supraventricular Tachycardia
Interventions
Dual Chamber ICD, Single Chamber ICD
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 24, 2014 · Synced Oct 21, 2026, 1:35 AM EDT
Terminated Phase 3 Interventional Results available

Catheter Ablation Versus Amiodarone for Shock Prophylaxis in Defibrillator Patients With Ventricular Tachycardia

NCT01097330
View directory record Official record
Conditions
Defibrillators, Implantable, Tachycardia, Ventricular
Interventions
Ablation, Amiodarone
Procedure · Drug
Lead sponsor
Population Health Research Institute
Other
Eligibility
19 Years to 84 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
5
States / cities
Chicago, Illinois • Rochester, Minnesota • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2020 · Synced Oct 21, 2026, 1:35 AM EDT
Completed No phase listed Observational

Prevention of Retained-Blood Outcomes With Active Clearance Technology

NCT02145858
View directory record Official record
Conditions
Hemorrhage, Atrial Fibrillation, Postoperative
Interventions
Blood drainage post cardiac surgery using PleuraFlow System
Device
Lead sponsor
ClearFlow, Inc.
Industry
Eligibility
18 Years and older
Enrollment
891 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
Manchester, New Hampshire • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 17, 2018 · Synced Oct 21, 2026, 1:35 AM EDT
Completed Not applicable Interventional

PREPARE - Primary Prevention Parameters Evaluation

NCT00279279
View directory record Official record
Conditions
Tachycardia, Ventricular, Implantable Cardioverter Defibrillator (ICD), Fibrillation, Ventricular, Syncope
Interventions
Implanted Device
Device
Lead sponsor
Medtronic Cardiac Rhythm and Heart Failure
Industry
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
31
States / cities
Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2006 · Synced Oct 21, 2026, 1:35 AM EDT
Completed No phase listed Observational

Real-world Comparative Effectiveness of Rivaroxaban Versus VKA

NCT02690155
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Rivaroxaban (Xarelto, BAY59-7939), VKA (Vitamin K antagonist)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
38,831 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 5, 2017 · Synced Oct 21, 2026, 1:35 AM EDT
Withdrawn Not applicable Interventional

Can the Lambre Device Occlude IRRegular And Large Appendages in Patients With Non-Valvular AF

NCT04684212
View directory record Official record
Conditions
Atrial Fibrillation, Left Atrial Appendage Thrombosis, CVA
Interventions
LAmbre PlusTM Left Atrial Appendage Closure System, Market approved oral anticoagulation (OAC), such as warfarin (Coumadin), dabigatran (Pradaxa), rivaroxaban (Xarelto), apixiban (Eliquis), edoxaban (Savaysa), or betrixaban (Bevyxxa)
Device · Drug
Lead sponsor
Brian O'Neill MD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Oct 21, 2026, 1:35 AM EDT
Completed Not applicable Interventional

Electronic Alerts for Stroke Prevention in Atrial Fibrillation

NCT02958943
View directory record Official record
Conditions
Atrial Fibrillation, Stroke
Interventions
On-screen electronic alert
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
798 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 8, 2022 · Synced Oct 21, 2026, 1:35 AM EDT
Terminated Phase 3 Interventional Results available

Ranolazine for the Prevention of Atrial Fibrillation After Electrical Cardioversion

NCT01349491
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Ranolazine, Matching placebo
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
21 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 27, 2017 · Synced Oct 21, 2026, 1:35 AM EDT
Completed Phase 3 Interventional

Evaluating the Use of SR34006 Compared to Warfarin or Acenocoumarol in Patients With Atrial Fibrillation (AMADEUS)

NCT00070655
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
SR34006 (idraparinux sodium) Injection, vitamin K antagonist (warfarin or acenocoumarol) tablets
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
4,673 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
41
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2011 · Synced Oct 21, 2026, 1:35 AM EDT
Recruiting Not applicable Interventional

Carotid Implants for PreveNtion of STrokE ReCurrEnce From Large Vessel Occlusion in Atrial Fibrillation Patients Treated With Oral Anticoagulation

NCT05723926
View directory record Official record
Conditions
Atrial Fibrillation, Oral Anticoagulation, Stroke, Implant
Interventions
Vine Filter
Device
Lead sponsor
Javelin Medical
Industry
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
6
States / cities
Rockford, Illinois • Boston, Massachusetts • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 21, 2026, 1:35 AM EDT
Completed Phase 4 Interventional Results available

Prevention of Atrial Fibrillation Following Noncardiac Thoracic Surgery

NCT00127712
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Amiodarone
Drug
Lead sponsor
Indiana University
Other
Eligibility
40 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 18, 2013 · Synced Oct 21, 2026, 1:35 AM EDT
Completed Phase 3 Interventional Results available

Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate

NCT00262600
View directory record Official record
Conditions
Atrial Fibrillation, Stroke
Interventions
warfarin, Dabigatran dose 1, Dabigatran dose 2
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
18,113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
374
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 286 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2019 · Synced Oct 21, 2026, 1:35 AM EDT
Completed No phase listed Observational

Real-world Dosing Patterns of Rivaroxaban in the United States

NCT03242278
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Rivaroxaban (Xarelto, BAY59-7939)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
12,507 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Oct 21, 2026, 1:35 AM EDT
Completed Phase 3 Interventional Results available

Colchicine For The Prevention Of Perioperative Atrial Fibrillation In Patients Undergoing Thoracic Surgery (COP-AF)

NCT03310125
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Flutter, Myocardial Injury After Non-Cardiac Surgery
Interventions
Active Colchicine, Active Placebo
Drug
Lead sponsor
Population Health Research Institute
Other
Eligibility
55 Years and older
Enrollment
3,209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
8
States / cities
Weston, Florida • Detroit, Michigan • Stony Brook, New York + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 21, 2026, 1:35 AM EDT
Recruiting Early Phase 1 Interventional

Prevention of Postoperative Atrial Fibrillation (POAF) Using Intra-Pericardial Amiodarone

NCT06063538
View directory record Official record
Conditions
Atrial Fibrillation, Post-Op Complication
Interventions
CardiaMend in Combination with Amiodarone
Combination Product
Lead sponsor
University of Chicago
Other
Eligibility
20 Years to 85 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 21, 2026, 1:35 AM EDT
Completed Phase 3 Interventional Results available

Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation

NCT00412984
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Flutter
Interventions
warfarin, apixaban
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
Not listed
Enrollment
20,976 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
284
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 206 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2018 · Synced Oct 21, 2026, 1:35 AM EDT
Not listed Phase 4 Interventional

Efficacy of Different Anti-Thrombotic Strategies on Device-Related Thrombosis Prevention After Percutaneous Left Atrial Appendage Occlusion

NCT04502017
View directory record Official record
Conditions
Device-Related Thrombosis, Atrial Fibrillation, Left Atrial Appendage Occlusion
Interventions
ASA plus Clopidogrel, Genetic-Tailored AntiThrombotic Strategy, Half-Dose of novel OAC
Drug
Lead sponsor
Texas Cardiac Arrhythmia Research Foundation
Other
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 7, 2020 · Synced Oct 21, 2026, 1:35 AM EDT
Recruiting Phase 3 Interventional

Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable

NCT07430956
View directory record Official record
Conditions
Atrial Fibrillation (AF)
Interventions
REGN7508, REGN9933, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
2,628 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
43
States / cities
Dothan, Alabama • Glendale, Arizona • Little Rock, Arkansas + 37 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 21, 2026, 1:35 AM EDT